Compare Norwegian Cruise Line Holdings Ltd (NCLH) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norwegian Cruise Line Holdings Ltd vs Regeneron Pharmaceuticals Inc — how do they compare? Norwegian Cruise Line Holdings Ltd trades at $14.97 (market cap $7.07B), while Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 11.8× Norwegian Cruise Line Holdings Ltd's market cap, and Regeneron Pharmaceuticals Inc pays a 0.46% dividend while Norwegian Cruise Line Holdings Ltd pays none. Which is the better fit depends on your goals.
| NCLH | REGN | |
|---|---|---|
Market Cap | $7.07B | $83.43B |
Sector | Consumer Cyclical | Health |
52-Week High | $26.94 | $852.03 |
52-Week Low | $14.79 | $555.51 |
Enterprise Value | $21.88B | $78.14B |
Dividend Yield | — | 0.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norwegian Cruise Line Holdings (NCLH) trades at $15.39, down 1.16% with bearish technical signals despite recent earnings beats. The company shows improving fundamentals with $9.83B revenue and $423M net income in 2025, while maintaining attractive valuation metrics including P/E of 9.33 and P/S of 0.74. Recent news highlights fuel cost pressures from rising oil prices, though the company continues fleet expansion with new waterpark and ship developments.
NCLH presents a mixed outlook with strong analyst support (50% buy ratings, $20.25 target) but faces near-term headwinds from fuel costs and yield pressures. The stock offers value appeal with discounted valuation, though high leverage and operational challenges require monitoring for sustained recovery.
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
